These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 8043024)

  • 1. Inhibitory effect of the nonpeptide angiotensin II receptor antagonist losartan and its active metabolite, E-3174, on cAMP phosphodiesterase: additional action of the antagonists.
    Ishizaki H; Ohtawa M
    Biochem Pharmacol; 1994 Jul; 48(1):201-4. PubMed ID: 8043024
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Different types of receptor interaction of peptide and nonpeptide angiotensin II antagonists revealed by receptor binding and functional studies.
    Wienen W; Mauz AB; Van Meel JC; Entzeroth M
    Mol Pharmacol; 1992 Jun; 41(6):1081-8. PubMed ID: 1614410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro and in vivo effects of UP 269-6, a new potent orally active nonpeptide angiotensin II receptor antagonist, on vascular smooth muscle cell proliferation.
    Virone-Oddos A; Desangle V; Provost D; Cazes M; Caussade F; Cloarec A
    Br J Pharmacol; 1997 Feb; 120(3):488-94. PubMed ID: 9031754
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interaction of nonpeptide angiotensin II receptor antagonists with the urate transporter in rat renal brush-border membranes.
    Edwards RM; Trizna W; Stack EJ; Weinstock J
    J Pharmacol Exp Ther; 1996 Jan; 276(1):125-9. PubMed ID: 8558420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BMS-180560, an insurmountable inhibitor of angiotensin II-stimulated responses: comparison with losartan and EXP3174.
    Dickinson KE; Cohen RB; Skwish S; Delaney CL; Serafino RP; Poss MA; Gu Z; Ryono DE; Moreland S; Powell JR
    Br J Pharmacol; 1994 Sep; 113(1):179-89. PubMed ID: 7812609
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological profile of valsartan: a potent, orally active, nonpeptide antagonist of the angiotensin II AT1-receptor subtype.
    Criscione L; de Gasparo M; Bühlmayer P; Whitebread S; Ramjoué HP; Wood J
    Br J Pharmacol; 1993 Oct; 110(2):761-71. PubMed ID: 8242249
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological profile of a highly potent and long-acting angiotensin II receptor antagonist, 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4- yl]methyl]-1H-benzimidazole-7-carboxylic acid (CV-11974), and its prodrug, (+/-)-1-(cyclohexyloxycarbonyloxy)-ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5- yl)biphenyl-4-yl]methyl]-1H-benzimidazole-7-carboxylate (TCV-116).
    Shibouta Y; Inada Y; Ojima M; Wada T; Noda M; Sanada T; Kubo K; Kohara Y; Naka T; Nishikawa K
    J Pharmacol Exp Ther; 1993 Jul; 266(1):114-20. PubMed ID: 8331552
    [TBL] [Abstract][Full Text] [Related]  

  • 8. KS-505a, an isoform-selective inhibitor of calmodulin-dependent cyclic nucleotide phosphodiesterase.
    Ichimura M; Eiki R; Osawa K; Nakanishi S; Kase H
    Biochem J; 1996 May; 316 ( Pt 1)(Pt 1):311-6. PubMed ID: 8645223
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective inhibition of cyclic nucleotide phosphodiesterases of human, bovine and rat aorta.
    Lugnier C; Schoeffter P; Le Bec A; Strouthou E; Stoclet JC
    Biochem Pharmacol; 1986 May; 35(10):1743-51. PubMed ID: 2423089
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo pharmacology of L-158,809, a new highly potent and selective nonpeptide angiotensin II receptor antagonist.
    Siegl PK; Chang RS; Mantlo NB; Chakravarty PK; Ondeyka DL; Greenlee WJ; Patchett AA; Sweet CS; Lotti VJ
    J Pharmacol Exp Ther; 1992 Jul; 262(1):139-44. PubMed ID: 1625193
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nonpeptide angiotensin II antagonist losartan inhibits thromboxane A2-induced contractions in canine coronary arteries.
    Li P; Ferrario CM; Brosnihan KB
    J Pharmacol Exp Ther; 1997 Jun; 281(3):1065-70. PubMed ID: 9190837
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lack of a centrally-mediated antihypertensive effect following acute or chronic central treatment with AT1-receptor antagonists in spontaneously hypertensive rats.
    Bunting MW; Widdop RE
    Br J Pharmacol; 1995 Dec; 116(8):3181-90. PubMed ID: 8719794
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Nonpeptide angiotensin II receptor antagonists].
    Nishikawa K
    Tanpakushitsu Kakusan Koso; 1993 Aug; 38(11):1873-80. PubMed ID: 8210431
    [No Abstract]   [Full Text] [Related]  

  • 14. [Nonpeptide angiotensin II antagonists].
    Shionoiri H; Takasaki I; Sugimoto K; Minamisawa K
    Nihon Rinsho; 1992 Apr; 50 Suppl():753-63. PubMed ID: 1635263
    [No Abstract]   [Full Text] [Related]  

  • 15. Inhibition of sympathetic outflow by the angiotensin II receptor antagonist, eprosartan, but not by losartan, valsartan or irbesartan: relationship to differences in prejunctional angiotensin II receptor blockade.
    Ohlstein EH; Brooks DP; Feuerstein GZ; Ruffolo RR
    Pharmacology; 1997 Nov; 55(5):244-51. PubMed ID: 9399334
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological profile of GR117289 in vitro: a novel, potent and specific non-peptide angiotensin AT1 receptor antagonist.
    Robertson MJ; Barnes JC; Drew GM; Clark KL; Marshall FH; Michel A; Middlemiss D; Ross BC; Scopes D; Dowle MD
    Br J Pharmacol; 1992 Dec; 107(4):1173-80. PubMed ID: 1467838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Angiotensin-II activation of cAMP and corticosterone production in bovine adrenocortical cells: effects of nonpeptide angiotensin-II antagonists.
    Rainey WE; Byrd EW; Sinnokrot RA; Carr BR
    Mol Cell Endocrinol; 1991 Oct; 81(1-3):33-41. PubMed ID: 1665830
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Angiotensin II receptor antagonists: the prototype losartan.
    Schaefer KL; Porter JA
    Ann Pharmacother; 1996 Jun; 30(6):625-36. PubMed ID: 8792950
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention of thromboxane A2 receptor-mediated pulmonary hypertension by a nonpeptide angiotensin II type 1 receptor antagonist.
    Bertolino F; Valentin JP; Maffre M; Jover B; Bessac AM; John GW
    J Pharmacol Exp Ther; 1994 Feb; 268(2):747-52. PubMed ID: 8113986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo pharmacology of a novel AT1 selective angiotensin II receptor antagonist, MK-996.
    Kivlighn SD; Zingaro GJ; Gabel RA; Broten TP; Schorn TW; Schaffer LW; Naylor EM; Chakravarty PK; Patchett AA; Greenlee WJ
    Am J Hypertens; 1995 Jan; 8(1):58-66. PubMed ID: 7734099
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.